Hormone Replacement Therapy Market

Hormone Replacement Therapy Market

Hormone Replacement Therapy Market to Reach US$ 36.4 bn by 2032, driven by the rising incidence of target diseases and the availability of long-acting hGH products: Global Insight Services

New York, July  2023: According to a new research study by Global Insight Services (GIS), the global Hormone Replacement Therapy Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 36.4 bn by 2032.

hormone replacement therapy (HRT) is a treatment technique for replacing and/or replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body. The most prominent application of HRT is in the treatment of symptom alleviation of menopause.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS21882

Hormone Replacement Therapy Market: Key Trends and Drivers

One significant growth driver for the Hormone Replacement Therapy (HRT) market is the increasing awareness and acceptance of hormone replacement therapies for managing symptoms associated with menopause. As more women become educated about the benefits of HRT in alleviating hot flashes, night sweats, vaginal dryness, and other menopausal symptoms, the demand for these therapies is expected to rise. Moreover, with advancements in medical research and technology, the development of innovative and more targeted hormone therapies has become possible, catering to individual patient needs and preferences. This expanding range of treatment options, coupled with a growing aging population worldwide, is anticipated to fuel the growth of the HRT market in the coming years.

Hormone Replacement Therapy Market: Restraints & Challenges

One of the key restraints in the Hormone Replacement Therapy (HRT) market is the potential risk associated with long-term use of hormone replacement products. While HRT can provide relief from menopausal symptoms and other hormonal imbalances, studies have suggested an increased risk of certain health conditions, such as cardiovascular diseases and certain types of cancer, with prolonged use of HRT. These safety concerns have led to cautious prescribing practices and decreased patient acceptance, limiting the growth potential of the HRT market. Additionally, the availability of alternative therapies and the preference for non-hormonal treatment options further restraining the market growth.

Hormone Replacement Therapy Market Report Findings

https://www.globalinsightservices.com/reports/hormone-replacement-therapy-market/

The estrogen and progesterone replacement therapy segment is anticipated to hold a majority of the Hormone Replacement Therapy Market size throughout the study period.

Based on Therapy Type, it is analyzed across Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, and Progestogen Hormone Replacement Therapy. Among these, the estrogen and progesterone replacement therapy segment emerged as the dominant market leader in the Hormone Replacement Therapy industry. This significant market share can be attributed to the rising demand for hormone replacement therapies among individuals experiencing hormonal imbalances or undergoing menopause. According to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause daily in the U.S. Estrogen and progesterone replacement therapies are widely used to alleviate symptoms and promote overall well-being, thereby driving the growth of this particular segment in the Hormone Replacement Therapy market.

Moreover, advancements in Hormone Replacement Therapy technologies and the availability of innovative delivery systems have further propelled the adoption of estrogen and progesterone replacement therapy. As the aging population continues to expand globally and individuals seek ways to manage hormonal imbalances and associated symptoms, the estrogen and progesterone replacement therapy segment is expected to maintain its strong market position. The Hormone Replacement Therapy market will continue to witness significant growth, driven by the increasing demand for hormone replacement products and ongoing research to develop novel peptides that offer enhanced efficacy and improved patient outcomes.

The parenteral segment is likely to hold a dominant Hormone Replacement Therapy Market share and grow at a substantial CAGR during the forecast period.

Based on route of administration, it is categorized into parenteral, oral, and transdermal. During the projected period, the parenteral segment is anticipated to experience significant growth. This growth can be attributed to advancements in drug delivery methods, particularly through pen-based drug delivery systems. These systems are expected to enhance patient compliance and simplify administration, thus driving the expansion of this segment. Some popular pen-based products include the Genotropin Mixer Pen, Norditropin FlexPro Pen, and Humatrope HumatroPen.

Additionally, the introduction of a new long-acting growth hormone injection is predicted to further fuel the growth of this segment. For example, in January 2022, Pfizer, Inc. and OPKO Health, Inc. obtained approval from the Ministry of Health, Labour and Welfare in Japan to market NGENLA, a next-generation long-acting growth hormone injection for treating growth hormone disorders. This product offers the advantage of a once-a-week dosage regimen, contributing to its potential impact on segment growth.

The hypothyroidism Companies segment is anticipated to hold a majority of the Hormone Replacement Therapy Market size throughout the study period.

On the basis of Indication, it is segmented into Hypothyroidism, Menopause, Male Hypogonadism, Growth Hormone Deficiency, and Others. In 2022, the the hypoparathyroidism segment is anticipated to experience substantial growth in the forecast period, driven by the development of novel treatments and the introduction of new products. For instance, in September 2020, Ascendis Pharma A/S presented its TransCon technologies at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting. The company also disclosed the top-line results of the phase 2 clinical trial for TransCon PTH at the same event. Currently, the drug is undergoing phase 3 clinical trials. Upon approval and subsequent launch, this product will offer additional options for parathyroid hormone replacement therapy

On the other hand, menopause segment emerged as the dominant force in the market, capturing a share. This can be attributed to the rising number of women experiencing menopause. According to the UN’s 2020 global estimates, there were 958 million women aged 50 and above, and this number is projected to reach 1.65 billion by 2050. As a result, a significant population of women is expected to spend a considerable portion of their lives after menopause in the future. However, the age of menopause can vary due to various factors, including natural factors such as habitat and genetics, which influence the timing of menopause for individuals.

The North America region is estimated to exhibit the highest growth rate during the Hormone Replacement Therapy Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is projected to maintain its dominant position in the Hormone Replacement Therapy market throughout the forecast period. This region is expected to experience substantial growth throughout the forecast period. The significant market share can be attributed to several factors, including major product launches, collaborative agreements among manufacturers, and favorable reimbursement policies. An example of such a success is the approval of Sogroya (somapacitan-beco), a hormone replacement therapy product developed by Novo Nordisk A/S, by the U.S. FDA in August 2020. This particular product is administered once weekly via the subcutaneous route and is targeted towards adults diagnosed with growth hormone deficiency. The region’s strong healthcare infrastructure, increasing geriatric population, rising prevalence of hormonal disorders, and extensive research and development activities contribute to its leadership position. Additionally, favorable reimbursement policies, high healthcare expenditure, and robust pharmaceutical industry further propel the growth of the HRT market in North America, attracting both domestic and international players to invest in this lucrative market segment..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS21882/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Hormone Replacement Therapy market include AbbVie (U.S.), Allergan plc (U.S.), Amgen (U.S.), Bayer AG (Germany), Belmar Pharma Solutions (U.S.), Endo International plc (Ireland), Merck KGaA (Germany), Mithra Pharmaceuticals (Belgium), Novo Nordisk A/S (Denmark), and Pfizer Inc. (U.S.)., among others.

Recent Developments in the Hormone Replacement Therapy Market:

  • In February 2023, Korea’s Ministry of Food and Drug Safety approved Pfizer’s NGENLA for the treatment of growth hormone deficiency.
  • In June 2022, Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
  • In February 2022, Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
  • In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labour and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorder. This product is the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage.
  • In November 2021, I-MAB Biopharma Co., Ltd. entered into a collaboration with Jumpcan Pharmaceutical Group for the development & commercialization of eftansomatropin alfa (TJ101) in China. TJ101 is a long-acting recombinant human growth hormone, which is currently under phase 3 clinical trial for the treatment of pediatric growth hormone deficiency. This collaboration is expected to strengthen its position in the hormone replacement therapy market.
  • In September 2020, Ascendis Pharma A/S showcased the TransCon technologies at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting. It also published the top-line results of the phase 2 clinical trial for TransCon PTH at the annual meeting. The drug is currently in phase 3 clinical trials. The approval and subsequent launch of this product will provide more options available for parathyroid hormone replacemen
  • In August 2020, U.S. FDA approved Sogroya (somapacitan-beco) a HGH replacement therapy product developed by Novo Nordisk A/S. This product is administered once a weekly through subcutaneous route in adults diagnosed with growth hormone deficiency.

Hormone Replacement Therapy Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Hormone Replacement Therapy Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Hormone Replacement Therapy market in terms of revenue ($Million)
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Hormone Replacement Therapy Market industry.
  • A thorough analysis of market trends and restraints is provided
  • By region as well as country market analysis is also presented in this report
  • Analytical depiction of the Hormone Replacement Therapy Market along with the current trends and future estimations to depict imminent investment pockets. The overall Hormone Replacement Therapy Market Industry opportunity is examined by understanding profitable trends to gain a stronger foothold
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Hormone Replacement Therapy Market are also analyzed.

Global Hormone Replacement Therapy Market Segmentation

By Therapy Type

  • Estrogen Hormone Replacement Therapy
  • Human Growth Hormone Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Hormone Replacement Therapy
  • Progestogen Hormone Replacement Therapy

By Route of Administration

  • Oral
  • Parenteral
  • Transdermal

By Indication

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Others

By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Key Players